Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension

Abstract

Hypertension (HTN) significantly contributes to worldwide morbidity and mortality [Citation1,Citation2]. It impacts around 1.3 billion individuals globally, rendering it one of the most prevalent cardiovascular diseases [Citation1]. Although several classes of antihypertensive drugs have shown efficacy in managing hypertension, many patients continue to have elevated blood pressure (BP) despite being on multiple medications. This condition, known as resistant hypertension (rHTN), occurs when BP does not respond adequately to at least three antihypertensive agents, including a diuretic, calcium channel blocker, and renin-angiotensin system blocker, even when patient compliance is not a culprit [Citation3]. The fact that rHTN increases the risk of severe complications highlights the urgency for efficacious therapies.